MedTrace Logo

Immunologic Action of a Single Dose Cholecalciferol

NCT01845142 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-06-25

No results posted yet for this study

Summary

Vitamin D receptors are expressed in activated different immune cells. It is not known, which immune cell type is targeted by exogenous vitamin D. Here, vitamin D-deficient individuals will receive once 100.000 I.U. vitamin D3 either intramuscular or subcutaneous in a double-blind placebo controlled setting. Immune cells will be monitored from the blood over time.

Conditions

  • Vitamin D Deficiency

Interventions

DRUG

single administration of 100.000 I.U. vitamin D

DRUG

Placebo

Sponsors & Collaborators

  • Margitta Worm

    lead OTHER

Principal Investigators

  • Margitta Worm, Prof · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-05-31
Completion
2014-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845142 on ClinicalTrials.gov